X-CircuiT and conventional exercise in home-based cardiac rehabilitation for patients with coronary artery disease and risk factors: a randomized controlled non-inferiority trial

Scritto il 15/09/2025
da Xun Gong

Ann Med. 2025 Dec;57(1):2558124. doi: 10.1080/07853890.2025.2558124. Epub 2025 Sep 15.

ABSTRACT

INTRODUCTION: This study evaluated the effectiveness of Xiangya Hospital Circuit Training (X-CircuiT), a multi-component exercise program, as an alternative to conventional exercise (ConEx) in improving cardiorespiratory and muscular fitness within home-based cardiac rehabilitation (HBCR) for patients with coronary artery disease and risk factors (CADRF).

PATIENTS AND METHODS: This randomized controlled non-inferiority trial consecutively enrolled patients with CADRF at Xiangya Hospital, China, between April and December 2020. Patients were assigned to a smartphone-guided X-CircuiT-HBCR or telephone call-guided ConEx-HBCR group for 12 weeks. Primary outcomes were cardiorespiratory fitness (peak oxygen uptake, Opeak), and muscular fitness (30-sec arm curl and chair stand tests). The non-inferiority margins were 2.17 mL/kg/min, 2.70 reps, and 1.23 reps, respectively. Secondary outcomes included O pulse, O at ventilatory threshold, balance, flexibility, body mass index, health-related quality of life (HRQoL), self-efficacy, physical activity, safety, and exercise adherence.

RESULTS: This trial included 54 participants (median age 53 yr, 37% females), with 27 per group. Both groups showed significant improvements in fitness. There were no significant differences between groups in the improvements in Opeak (mean difference, -0.13 [95%CI, -1.76 to 1.50] mL/kg/min), arm curl test (0.21 [-1.35 to 1.77] reps), and chair stand test (1.30 [-0.18 to 2.77] reps), with 95% CIs within the non-inferiority range. No significant differences were found in HRQoL, self-efficacy, and exercise adherence (all p > .05). No adverse events occurred.

CONCLUSIONS: X-CircuiT is non-inferior to ConEx in HBCR for CADRF patients, suggesting it as an effective alternative or supplement in HBCR programs.

TRIAL REGISTRATION NUMBER: ChiCTR2000032451.

PMID:40947912 | PMC:PMC12439806 | DOI:10.1080/07853890.2025.2558124